Affiliation:
1. Universidade Federal do Paraná, Brasil
Abstract
SUMMARYChromoblastomycosis (CMB) is a chronic fungal infection of the skin and the subcutaneous tissue caused by a transcutaneous traumatic inoculation of a specific group of dematiaceous fungi occurring mainly in tropical and subtropical zones worldwide. If not diagnosed at early stages, patients with CBM require long term therapy with systemic antifungals, sometimes associated with physical methods. Unlike other neglected endemic mycoses, comparative clinical trials have not been performed for this disease. Nowadays, therapy is based on a few open trials and on expert opinion. Itraconazole either as monotherapy or associated with other drugs, or with physical methods, is widely used. Recently, photodynamic therapy has been successfully employed in combination with antifungals in patients presenting with CBM. In the present revision the most used therapeutic options against CBM are reviewed as well as the several factors that may have impact on the patient's outcome.
Subject
Infectious Diseases,General Medicine
Reference38 articles.
1. Occupational mycoses;AL-DOORY Y,1983
2. Treatment of severe chromoblastomycosis with itraconazole and 5-flucytosine association;Antonello VS;Rev Inst Med Trop Sao Paulo,2010
3. Chromoblastomycosis: a clinical and mycological study of 71 cases from Sri Lanka;Attapattu MC;Mycopathologia,1997
4. Revisiting the clinical and histopathological aspects of patients with chromoblastomycosis from the Brazilian Amazon region;Avelar-Pires C;Arch Med Res,2013
5. Traitement de quatre cas de chromomycose àFonsecaea pedrosoipar l'association 5-fluorocytosine-itraconazole;Bolzinger T;Nouv Dermatol,1991
Cited by
52 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献